Preclinical and clinical properties of trimegestone: A potent and selective progestin

  title={Preclinical and clinical properties of trimegestone: A potent and selective progestin},
  author={R{\'e}gine Sitruk-Ware and Ronald Bossemeyer and P R Bouchard},
  journal={Gynecological Endocrinology},
  pages={310 - 319}
Trimegestone (TMG) is a novel, 19-norpregnane progestin with potent and selective properties. In preclinical studies, TMG has been shown to provide high endometrial selectivity. Further, TMG has high affinity and selectivity for the progesterone receptor and lacks the agonist effects of other steroid hormones. In clinical studies, TMG has been shown to have high endometrial safety and an improved bleeding profile along with improved tolerability compared with other progestins. In addition, TMG… Expand
The use of newer progestins for contraception.
Several new progestins have been designed to minimize side-effects related to androgenic, estrogenic or glucocorticoid receptor (GR) interactions, and Dienogest (DNG) and drospirenone (DRSP) exhibit a partial antiandrogenic action, and DRSP has predominant anti-mineraloc Corticoid properties. Expand
A new strategy for selective targeting of progesterone receptor with passive antagonists.
The synthesis and characterization of a novel class of PR antagonists (APRn) designed from x-ray crystallographic studies are reported, suggesting that it belongs to a new class of pure antiprogestins that inactivate PR by a passive mechanism. Expand
Single-dose pharmacokinetics and pharmacodynamics assessment of oestriol and trimegestone containing vaginal rings in healthy women with childbearing potential
The Test 3 formulation presented the best dose combination of E3/TMG for contraception as well as well tolerated, and all vaginal rings were well tolerated. Expand
Contraceptives with novel benefits
The newer PR agonists including drospirenone, nomegestrol, trimegestone, dienogest and nestorone are being evaluated as contraceptives with health benefits because of their unique pharmacological properties. Expand
Ovulation inhibition with a new vaginal ring containing trimegestone.
The vaginal ring releasing TMG seems to be an effective new progestogen-only contraceptive preparation, having the advantage of once-a-month vaginal insertion. Expand
Developmental reprogramming of rat GLUT5 requires glucocorticoid receptor translocation to the nucleus
The glucocorticoid receptor (GR) antagonist RU486 dose‐dependently prevented the dexamethasone‐mediated effects on body weight, intestinal arginase2 (a known GR‐regulated gene) and GLUT5, and an antagonist of the mineralocortioid receptor as well as agonists of progesterone and pregnane‐X (PXR) receptors did not block the effects of dexamETHasone. Expand
Contraceptive Technologies: Looking Ahead to New Approaches to Increase Options for Family Planning
Methods under development aim to reduce potential side effects, improve access and ease of use, ensure safety, increase secondary benefits associated with method use and expand options for both women and men. Expand
  • C. Tamminga
  • Medicine, Psychology
  • The American journal of psychiatry
  • 2006
Coon, Katharine, Jessica Ogden, John Odolon, Anthony Obudi-Owor, Charles Otim, James Byakigga, and Peter Spebanja. “Transcending boundaries to improve the food security of HIV-affected households inExpand
Research that makes a difference.
  • L. Issel
  • Computer Science, Medicine
  • Health care management review
  • 2016
By 2030 each of the major regions of the developing world will hold more urban than rural dwellers, according to the World Bank. Expand


The preclinical biology of a new potent and selective progestin: trimegestone
The results indicate that TMG is a potent and selective progestin with a preclinical profile well suited for hormone replacement therapy, which may translate into fewer mood-related side effects. Expand
In vitro characterization of trimegestone: a new potent and selective progestin
Data from several in vitro assays demonstrate that TMG is a potent progestin with a better receptor selectivity profile than MPA. Expand
The pharmacological profile of a novel norpregnance progestin (trimegestone).
Results show trimegestone to have a favorable pharmacological profile with potent progestomimetic activity, and to be not associated with any unwanted pharmacological effects. Expand
Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models.
Drospirenone represents a novel type of synthetic progestogen since it combines potent progestogenic characteristics with antimineralocorticoid and antiandrogenic activity and is anticipated to give rise to a number of additional health benefits both for users of oral contraceptives and hormone replacement therapy recipients. Expand
Conception and pharmacodynamic profile of drospirenone
DRSP prevented the mild increase of blood pressure seen under a conventional levonorgestrel-containing contraceptive and even tended to reduce pretreatment blood pressure, and powerful antiandrogenic effects were seen in gonad intact and testosterone substituted castrated male rats. Expand
Progestogens in hormonal replacement therapy: new molecules, risks, and benefits
Complying with the classic contraindications of HRT and selecting molecules devoid of estrogenic, androgenic, or glucocorticoid effect should allow a larger use of the progestins without any major drawback. Expand
Pharmacological profile of progestins.
Progestins with antiandrogenic properties may also be used for the treatment of women with preexisting androgen related conditions and may be considered as a fourth-generation of progestins. Expand
Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone
TMG was a more potent antagonist of estrogenic activity in the uterine endometrium than any of the reference progestins tested and therefore may be more effective in protecting theendometrium in hormone replacement therapy. Expand
Effects of 17β-estradiol and trimegestone alone ,and in combination ,on the bone and uterus of ovariectomized rats
Trimegestone is a novel norpregnane progestin being developed, in combination with 17β-estradiol, for the treatment of menopausal symptoms and prevention of postmenopausal osteoporosis and did not block the beneficial effects of 17 β-ESTradiol on bone. Expand
Anxiolytic Effect of Progesterone is Mediated by the Neurosteroid Allopregnanolone at Brain GABAA Receptors
Evidence is provided that the anxiolytic effect of PROG is not associated with an intracellular steroid receptor that initiates genomic‐mediated responses, and is consistent with a nongenomic mechanism whereby PROG is metabolized to allopregnanolone, a neuroactive steroid that potentiates GABAA receptor‐ mediated responses. Expand